Emily J. Girard

This study evaluates an intratumoral B7H3:CD3 TCE in canine sarcoma patients, showing localized T-cell accumulation without systemic toxicity.

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

This study investigates the combination of DNA methyltransferase inhibitor decitabine and PD-1 inhibitor in high-risk pediatric brain tumor models, finding improved survival in some subtypes.

CYpHER is a targeted protein degradation technology that uses pH-dependent release and the transferrin receptor to deliver drugs to endolysosomes, demonstrating potency and durability in vitro and in vivo.

This paper develops injectable hydrogels that enable controlled, extended release of protein therapeutics through hydrolysable linkers, demonstrating efficacy in a mouse melanoma model.

This study identifies BRG1 inhibition as a therapeutic strategy for CBFA2T3-GLIS2 AML by analyzing chromatin profiles and CRISPR dependencies.